Shopping Cart
Remove All
Your shopping cart is currently empty
Teclistamab (Alias: JNJ-64007957, JNJ64007957)
Catalog No. T76881 Copy Product Info
Purity: 95%
🥰Excellent
Teclistamab (JNJ-64007957) is a human bispecific monoclonal antibody targeting the CD3 receptor expressed on the surface of t-cells and the b-cell maturation antigen (BCMA) expressed on the surface of malignant multiple myeloma b-lineage cells for the treatment of relapsed and refractory multiple myeloma.
Teclistamab
Copy Product Info🥰Excellent
Catalog No. T76881
Alias JNJ-64007957, JNJ64007957
Teclistamab (JNJ-64007957) is a human bispecific monoclonal antibody targeting the CD3 receptor expressed on the surface of t-cells and the b-cell maturation antigen (BCMA) expressed on the surface of malignant multiple myeloma b-lineage cells for the treatment of relapsed and refractory multiple myeloma.
Teclistamab
Cas No. 2119595-80-9
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $689 | - | In Stock | |
| 5 mg | $1,590 | - | In Stock | |
| 10 mg | $2,180 | - | In Stock | |
| 25 mg | $3,230 | - | In Stock | |
| 50 mg | $4,370 | 8-10 weeks | 8-10 weeks | |
| 100 mg | $5,890 | 8-10 weeks | 8-10 weeks |
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Teclistamab (JNJ-64007957) is a human bispecific monoclonal antibody targeting the CD3 receptor expressed on the surface of t-cells and the b-cell maturation antigen (BCMA) expressed on the surface of malignant multiple myeloma b-lineage cells for the treatment of relapsed and refractory multiple myeloma. |
| In vitro | Methods: Frozen BM MNCs were treated with Teclistamab (0-532 nM) with or without exogenous healthy T cells to measure target engagement and killing. Results: Teclistamab-induced cytotoxicity in BM MNCs had comparable EC50s (1.5-4.2 nM) in all 3 patient samples; Teclistamab-mediated T cell activation was also similar in all BM MNC samples with EC50s (0.93 - 1.75 nM). [1] |
| Synonyms | JNJ-64007957, JNJ64007957 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFRSF17/BCMA/CD269 & CD3 |
| Molecular Weight | 143.64 kDa |
| Cas No. | 2119595-80-9 |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Teclistamab | purchase Teclistamab | Teclistamab cost | order Teclistamab | Teclistamab in vitro | Teclistamab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.